pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-4720 |
Genomic Coordinates | chr16: 81385018 - 81385093 |
Description | Homo sapiens miR-4720 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-4720-5p | ||||||||||||||||||||||||
Sequence | 4| CCUGGCAUAUUUGGUAUAACUU |25 | ||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||
Putative Targets |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | EBAG9 | ||||||||||||||||||||
Synonyms | EB9, PDAF | ||||||||||||||||||||
Description | estrogen receptor binding site associated, antigen, 9 | ||||||||||||||||||||
Transcript | NM_004215 | ||||||||||||||||||||
Other Transcripts | NM_198120 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on EBAG9 | |||||||||||||||||||||
3'UTR of EBAG9 (miRNA target sites are highlighted) |
>EBAG9|NM_004215|3'UTR 1 CACATGTTCAAATTTTATCATGCCAGTAGGAGAAATCTCAGCTCCACAACCCAAGCAACATTTGTATGGATTTAAGAGTA 81 TTTTAAGAAGACATACTGCTTGATTTTAATACATTGATCAGGCCATCCAGGACACCACGATTCTCCCAAAGTACCTTGAA 161 CTCTTAGTGATTGAGACTCAAAAAAACAAAAAAGACTTGAGACAATGTTTTCTTCAACATGCTCCAAATATAAGACATTT 241 GTTTGCTGTACAGAAAGTATCACAAATGGAATATATCAGTACCTCTCAAGCTAGTGTTTCTAGCTAAATAAATGGGTGTA 321 TATAATTTTATGGTGGAAAAGAACTGTACTGTCTGTTATGATTTCCTTCAATGTGCATAATGATAAAATAAATAATTTTA 401 ATATTCTTTTGTTTCCATGGTTACCTGACCTAAATTAGATAAATTGTAGGGCTTTAGCTTTCTTATTTTTGTCAAAAGTT 481 GGTGTTGACATACATTCCCTCTAATTTGAACTGGTATTGTTTACGTTTGATACAACATTAAGGAATTTGATGATTTTCAT 561 TTCATGAAAATGACATTAAATGCAATAATTTTACTTATCATAAACATTTTGTACATCATTATTTTCTTTTGGATTAGTGT 641 TGTCATACATGTAATTTATATCACATGTATAAACATTGAAAATCAACTAAAATGACATTTGTTCTACATTATAACTTGTG 721 AGTTTCAAGAACTAGTATTAGTAGTTTTTTCCTTTCATTATAGATTGTAAGATGTTGTGGTATCTTTGAGTGCCTTAGTT 801 CTTCCTTCCTCCCAAAAGCCATTAATTTACAAATGCTTAAAGCCATCAGGTCAAATATTTCAAAGCCTTTAGATGATTTC 881 TGTACTAGCTTTAGATGTCTGACGTTATGTAGGTTACCTGTGTTCTTGGCTAGGAAAACATTATTGATTCATTAAATCAT 961 AAAGGTGGGAATAATAATCTTTTATTTATGATGTTGATTGGCTCCAAAATAGTCTTAAGGAAATAAATACTGGGTCTGTA 1041 GGGGAAAAGTAGACTTCATAGTTTAAAATCCCATTAACCTTTTCACCGCAGTTGAAATGCATCCAGCCTGATTTTCCTAT 1121 CATTTTGGAATTTTTAAGGATTTTTACTTTCTTAAGTTACTGCCTAGAATCAACATTCGGTGAGATTTTGAAATGTCATA 1201 GATACTGTACAGGCCAAACCTTACTAATTTATTTTACTTAAAGTGATATTTTATAGAAAAATCATAAGTTATACAATGAG 1281 AACCCTTTAAGCCCTTAGCCTAAGCTTTCAGACTAAATGTGATTATAGAATAAGATGAAAGTTAACTTTGGTACAGAGCT 1361 TTTTATAGCCCCAAATTATATTTCCAGTTATTATATTCATTAGAATTTCTGCTAATAAACTCCCAACTTAAATAGAAAAA 1441 AAAAAAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | MCF7 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in SRR1045082. RNA binding protein: AGO2. Condition:Untreated
... - Farazi TA; Ten Hoeve JJ; Brown M; et al., 2014, Genome biology. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Farazi TA; Ten Hoeve JJ; Brown M; et al. - Genome biology, 2014
BACKGROUND: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets and pathway inference. RESULTS: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2 photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We then defined putative miRNA-target interactions using a computational model, which ranked and selected additional TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly, our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24 do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration. CONCLUSIONS: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing potential therapeutic targets and prognostic markers in breast cancer.
LinkOut: [PMID: 24398324]
|
CLIP-seq Support 1 for dataset SRR1045082 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | MCF7 / Untreated |
Location of target site | ENST00000337573.5 | 3UTR | UUCAAAUUUUAUCAUGCCAGUAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 24398324 / SRX388831 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
40 hsa-miR-4720-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT064869 | ZBTB18 | zinc finger and BTB domain containing 18 | 2 | 2 | ||||||||
MIRT099937 | SOX4 | SRY-box 4 | 2 | 2 | ||||||||
MIRT204534 | SLC39A10 | solute carrier family 39 member 10 | 2 | 4 | ||||||||
MIRT221679 | ZNRF2 | zinc and ring finger 2 | 2 | 2 | ||||||||
MIRT296659 | MRGBP | MRG domain binding protein | 2 | 6 | ||||||||
MIRT331634 | AASDHPPT | aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase | 2 | 2 | ||||||||
MIRT337078 | RER1 | retention in endoplasmic reticulum sorting receptor 1 | 2 | 2 | ||||||||
MIRT497580 | PTCHD4 | patched domain containing 4 | 2 | 2 | ||||||||
MIRT498838 | NAPEPLD | N-acyl phosphatidylethanolamine phospholipase D | 2 | 4 | ||||||||
MIRT502561 | EBAG9 | estrogen receptor binding site associated, antigen, 9 | 2 | 2 | ||||||||
MIRT508128 | AMD1 | adenosylmethionine decarboxylase 1 | 2 | 2 | ||||||||
MIRT511875 | GOLGA7 | golgin A7 | 2 | 6 | ||||||||
MIRT512924 | UBL4A | ubiquitin like 4A | 2 | 2 | ||||||||
MIRT513833 | KLHL15 | kelch like family member 15 | 2 | 6 | ||||||||
MIRT515889 | FAM182B | family with sequence similarity 182 member B | 2 | 2 | ||||||||
MIRT520201 | WASL | Wiskott-Aldrich syndrome like | 2 | 2 | ||||||||
MIRT526045 | GMDS | GDP-mannose 4,6-dehydratase | 2 | 2 | ||||||||
MIRT533601 | TNPO1 | transportin 1 | 2 | 2 | ||||||||
MIRT535539 | PAFAH1B2 | platelet activating factor acetylhydrolase 1b catalytic subunit 2 | 2 | 6 | ||||||||
MIRT541150 | PABPC1 | poly(A) binding protein cytoplasmic 1 | 2 | 4 | ||||||||
MIRT549609 | TMEM101 | transmembrane protein 101 | 2 | 2 | ||||||||
MIRT552630 | ZBTB41 | zinc finger and BTB domain containing 41 | 2 | 2 | ||||||||
MIRT555503 | PNISR | PNN interacting serine and arginine rich protein | 2 | 2 | ||||||||
MIRT560225 | PCNA | proliferating cell nuclear antigen | 2 | 2 | ||||||||
MIRT561671 | RAPGEF2 | Rap guanine nucleotide exchange factor 2 | 2 | 2 | ||||||||
MIRT562103 | ITGB1 | integrin subunit beta 1 | 2 | 2 | ||||||||
MIRT570710 | E2F3 | E2F transcription factor 3 | 2 | 2 | ||||||||
MIRT570802 | CKAP2L | cytoskeleton associated protein 2 like | 2 | 2 | ||||||||
MIRT615261 | DPF2 | double PHD fingers 2 | 2 | 2 | ||||||||
MIRT615389 | ZNF747 | zinc finger protein 747 | 2 | 2 | ||||||||
MIRT616621 | KCNJ11 | potassium voltage-gated channel subfamily J member 11 | 2 | 4 | ||||||||
MIRT641085 | ZKSCAN2 | zinc finger with KRAB and SCAN domains 2 | 2 | 2 | ||||||||
MIRT654971 | PLEKHA2 | pleckstrin homology domain containing A2 | 2 | 2 | ||||||||
MIRT667033 | PDE3A | phosphodiesterase 3A | 2 | 2 | ||||||||
MIRT677217 | RASSF6 | Ras association domain family member 6 | 2 | 2 | ||||||||
MIRT699243 | SLC6A8 | solute carrier family 6 member 8 | 2 | 2 | ||||||||
MIRT711673 | TRMT5 | tRNA methyltransferase 5 | 2 | 2 | ||||||||
MIRT713922 | CACNA2D1 | calcium voltage-gated channel auxiliary subunit alpha2delta 1 | 2 | 2 | ||||||||
MIRT722736 | BRMS1 | breast cancer metastasis suppressor 1 | 2 | 2 | ||||||||
MIRT724997 | CDC27 | cell division cycle 27 | 2 | 2 |
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|